BioInvent International
11.12.2021 23:46:53 CET | ACCESS Newswire | Press release
- Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma
- Complete responses lasting beyond 18, 24 and 36 months
LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces updated positive interim top-line data from its novel anti-FcyRIIB antibody BI-1206 that show increased response levels and sustained complete responses. The data represent the status - to early November 2021 - of the company's Phase 1/2a clinical trial of BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) treating patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). They are published today in a poster at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021).
The ASH 2021 poster shows that BI-1206 in combination with rituximab provided an objective response rate (ORR) of 54%, with three complete responses and four partial responses in 13 patients evaluated for therapeutic benefit for the three indications (Mantle cell lymphoma, Marginal zone lymphoma and Follicular lymphoma) enrolled in the clinical study. The treatment stabilized disease in one additional patient, giving a disease control rate of 62% (8 out of 13 patients).
When considered alone, the response rate for Follicular lymphoma is particularly impressive: of nine evaluable patients, three developed a CR, three developed a PR and one patient had SD at the cut-off date, giving a 67% ORR and 78% DCR. Previous rituximab treatments without BI-1206 had failed in these patients, prior to participation in the trial all patients had relapsed on earlier lines of rituximab-containing treatments.
All complete responses have been sustained for extended periods, with the longest complete response enduring beyond 36 months. In two additional patients, complete responses have lasted beyond 12 and 24 months after end of treatment.
"The current data are highly encouraging and already show the benefit of BI-1206 in rescuing rituximab treatment in advanced NHL. Without BI-1206, rituximab did not work well in these patients. Based on our deep understanding of the immune mechanisms at play, these data indicate that BI-1206 not only restores the anti-tumor response but does it safely and in a prolonged manner in many patients, notably in Follicular lymphoma. Adjusting the dosing regimen of BI-1206 could lead to yet further improvements. We look forward to discussing all these aspects with investors during our forthcoming KOL call on December 17," said Martin Welschof, PhD, CEO of BioInvent.
BioInvent will host a key opinion leader (KOL) webinar on BI-1206 featuring Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current NHL treatment landscape and unmet medical needs. Senior management will discuss the data presented at ASH 2021 and first data from the Phase 1/2a study of BI-1206 in combination with pembrolizumab for the treatment of solid tumors. The webinar will take place on Friday, December 17, 2021, at 1:00 pm ET/7:00 pm CET.
To register for the webinar, please click here .
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors. BI-1206 has also received approval to start clinical trials in China.
Since October 2020, BioInvent has a licensing agreement in place with CASI Pharmaceuticals for China, including Hong Kong, Macau, and Taiwan. Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological and solid cancers, with CASI responsible for commercialization in China and associated markets.
ASH 2021 will take place on December 11-14, 2021, at the Georgia World Congress Center - Atlanta, GA, and virtually. BioInvent's poster is entitled "Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcyRIIB, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab". The poster is presented today December 11 at 5.30 pm ET (11:30 pm CET).
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Disclaimer - BioInvent
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-11 23:30 CET.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/677141/BioInvents-Latest-NHL-Data-at-ASH-Show-Increased-and-Sustained-Responses-to-BI-1206-in-Relapsed-Patients
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Northfield Announces Change of Corporate Name to Juno International Corporation9.6.2026 21:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 9, 2026 / Northfield Capital Corporation (TSXV:NFD.A) (the "Corporation") today announced that it will change its corporate name to "Juno International Corporation" effective Thursday, June 11, 2026 (the "Name Change"). The trading symbol for the Corporation's class A restricted voting shares (the "Shares") will change to "JUN.A" following the completion of the Name Change. Trading of the Shares on the TSX Venture Exchange under the new name will commence at the open of markets on Thursday, June 11, 2026. There is no change in the capitalization of the Corporation in connection with the Name Change. No action is required by existing shareholders of the Corporation with respect to the Name Change. Outstanding certificates and Direct Registration Statement Advices with respect to the Shares do not need to be exchanged. Upon completion of the Name Change, the Company's new CUSIP number for the Shares will be 482045101 and its new ISIN number will be CA
WLF Energy and Farasis Energy Sign Strategic Partnership Agreement to Accelerate Next-Generation Energy Storage Solutions Globally9.6.2026 15:20:00 CEST | Press release
Partnership combines Farasis Energy's advanced battery technology leadership with WLF Energy's integrated energy platform, AI-driven optimization capabilities, and global deployment strategy STUTTGART, GERMANY / ACCESS Newswire / June 9, 2026 / WLF Energy and Farasis Energy today announced the signing of a Strategic Partnership Agreement to jointly develop, industrialize, and commercialize next-generation battery technologies and energy storage products for global markets. The partnership establishes a long-term framework for collaboration across battery cell technology, battery systems, energy management software, artificial intelligence, and large-scale deployment of energy storage solutions. Together, both companies aim to accelerate the transition toward more affordable, resilient, and sustainable energy infrastructure worldwide. The agreement combines Farasis Energy's extensive experience in advanced battery technology development and manufacturing with WLF Energy's integrated tec
WLF Energy Launches as Europe's Fast, Clean, Bold New Vertically Integrated Clean Energy Champion; Built to Power a Continent9.6.2026 13:30:00 CEST | Press release
Energy platform goes public at The Battery Show Stuttgart, targeting sub-10ct/kWh clean energy for everyone in Europe - and laying the foundation for the continent's energy independence in the decade ahead. STUTTGART, DE / ACCESS Newswire / June 9, 2026 / WLF Energy GmbH today made its public debut at The Battery Show Europe in Stuttgart, unveiling its fully integrated clean-energy platform and long-term mission to deliver affordable, intelligent and sovereign energy infrastructure at global scale. The announcement was delivered by CEO and Chairman Sebastian Wolf, marking the company's first public appearance before a global audience of battery industry leaders, technology innovators and energy investors. The debut signals the arrival of a new kind of European energy company - one designed to integrate generation, storage, intelligence and energy trading into a single platform capable of making clean power the most affordable form of energy in Europe. Founded in 2026, WLF Energy is dev
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park9.6.2026 13:00:00 CEST | Press release
Over 30,000 Attendees Celebrate the Sport of Polo and ‘An Icon Born from the Game' WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / June 9, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned for the third consecutive year as the Official Apparel and Jersey Partner of Chestertons Polo in the Park, bringing together world-class competition, sport-inspired fashion, thrilling entertainment, and memorable lifestyle experiences for one of London's most anticipated summer sporting events. Held June 5-7, 2026, at Hurlingham Park in central London, the three-day festival welcomed more than 30,000 attendees for a celebration of the sport of polo in one of the world's most iconic urban settings. The Red Sea Global Team Riyadh and the Disney+ Team Rivals fighting for the ball at Chestertons Polo in the Park As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all teams throughout the tournament with custom-designed perfor
7 Days Left: LiberNovo Maxis, Big & Tall's Ultimate Seat9.6.2026 11:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 9, 2026 / Built from the ground up for larger frames, the Maxis series launches June 16 starting at €829, with super early bird savings up to 48% off MSRP. For Big & Tall buyers, the ergonomic chair search usually starts with the spec sheet. Most chairs in this segment are built on the standard ergonomic envelope and scaled up, not designed for a larger body in the first place. LiberNovo's Maxis series, launching June 16, is the brand's first line engineered from the start for that body. It ships in three configurations alongside two new additions to the LiberNovo Omni family. A larger geometry, by design Standard ergonomic chairs are sized for a body that runs around 5'9" and 170 pounds. Maxis is sized for the bodies that don't fit those numbers. Its 52 cm seat extends fully under the thigh, so the front edge won't cut off circulation by mid-afternoon. The frame is BIFMA-certified to 181 kg (399 lb), supported by a die-cast aluminum alloy base th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom